Current Survey on Chemotherapy-Related Myelosuppression and Clinical Management in Chinese County-level Tumor Patients
The confirmed malignant tumor is one of the non-small cell lung cancer/small cell lung cancer/breast cancer/gastric cancer/esophageal cancer/colorectal cancer/gynecological malignant tumor (ovarian cancer, cervical cancer, endometrial cancer).
Patients who need to receive chemotherapy in the past 3 months and should continue to receive chemotherapy in the future
The relevant diagnosis and treatment information involved in the survey is complete: only patients with at least 1-2 examination results after 1 week after chemotherapy can be included
Understand and sign the informed consent form
Patients with concurrent chemoradiotherapy,
Patients with sequential chemoradiotherapy, and the irradiation site of radiotherapy is flat bone, sternum, and pelvis;
Patients with active bleeding before or during treatment; If the patient has received targeted drugs such as CDK4/6 inhibitors or chidaaniline in the front-line treatment, which have a great impact on the blood phase, the drug can be discontinued for at least half a month before it can be included
Patients who, in the opinion of other physicians, would cause non-chemotherapy-related myelosuppression
Chinese County-level Tumor Patients
Cohort
Retrospective
No intervention; Observational study
Other interventionNo intervention
Incidence of chemotherapy-related myelosuppression and current status of prophylactic therapy
The incidence and treatment status of chemotherapy-related myelosuppression were investigated in the form of questionnaires Like what： 1. Did bone marrow suppression occur after the previous cycle of chemotherapy? (First chemotherapy/occurrence/non-occurrence) 2. Did CIM (chemotherapy-induced myelosuppression) occur during this chemotherapy? (Multiple selections allowed) 3. Survey questions about existing CIM therapeutic drugs
Incidence of chemotherapy-related myelosuppression
Through questionnaire survey：the incidence of neutropenia during chemotherapy treatment and the rate of primary and secondary prophylaxis;
the rate and economic burden of neutropenia treatment during chemotherapy treatment
Through questionnaire survey：the rate and economic burden of neutropenia treatment during chemotherapy treatment like what:Is there an additional financial burden? A.\<500 yuan, B.500-\<1000 yuan, C.1000-\<3000 yuan, D.≥3000 yuan
the incidence of thrombocytopenia and the rate of primary and secondary prevention and treatment during chemotherapy treatment
Through questionnaire survey： the incidence of thrombocytopenia and the rate of primary and secondary prevention and treatment during chemotherapy treatment like what:Is there primary /secondary prevention in this chemotherapy? Yes/No
thrombocytopenia treatment rate and economic burden during chemotherapy treatment
Through questionnaire survey： thrombocytopenia treatment rate and economic burden during chemotherapy treatment like what：Does it increase the financial burden of patients to a certain extent? Yes/No
Click on the lead sponsor to view all of their trials.
The First Affiliated Hospital of Xinxiang Medical College
Lead sponsor
Xinxiang Central Hospital of Henan province
Collaborator
Linzhou People Hospital
Collaborator
Inner Huang County Traditional Chinese Hospital
Collaborator
Changyuan People Hospital
Collaborator
Huojia County People Hospital
Collaborator
Huojia County Alliance Hospital
Collaborator
Qinyang People Hospital
Collaborator
Xinan County People Hospital
Collaborator
Henan Hongli Hospital
Collaborator
Army Hospital of the 83rd Army
Collaborator
Anyang Cancer Hospital
Collaborator
Puyang Hospital of Traditional Chinese Medicine
Collaborator
Puyang Huimin Hospital
Collaborator
Hebi People Hospital
Collaborator
The Second People Hospital of Xinxiang Henan
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
